Shandong Lukang Pharmaceutical Co.,Ltd.

SHSE:600789 주식 보고서

시가총액: CN¥8.1b

Shandong Lukang PharmaceuticalLtd 과거 수익 실적

과거 기준 확인 4/6

Shandong Lukang PharmaceuticalLtd has been growing earnings at an average annual rate of 17.7%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 11.9% per year. Shandong Lukang PharmaceuticalLtd's return on equity is 10.3%, and it has net margins of 6.6%.

주요 정보

17.7%

수익 성장률

17.7%

EPS 성장률

Pharmaceuticals 산업 성장10.9%
매출 성장률11.9%
자기자본 수익률10.3%
순이익6.6%
최근 수익 업데이트30 Sep 2024

최근 과거 실적 업데이트

Shandong Lukang PharmaceuticalLtd's (SHSE:600789) Solid Profits Have Weak Fundamentals

Apr 03
Shandong Lukang PharmaceuticalLtd's (SHSE:600789) Solid Profits Have Weak Fundamentals

Recent updates

Does Shandong Lukang PharmaceuticalLtd (SHSE:600789) Have A Healthy Balance Sheet?

Sep 26
Does Shandong Lukang PharmaceuticalLtd (SHSE:600789) Have A Healthy Balance Sheet?

Shandong Lukang Pharmaceutical Co.,Ltd.'s (SHSE:600789) Price Is Out Of Tune With Earnings

Aug 21
Shandong Lukang Pharmaceutical Co.,Ltd.'s (SHSE:600789) Price Is Out Of Tune With Earnings

Is Shandong Lukang PharmaceuticalLtd (SHSE:600789) A Risky Investment?

Jun 03
Is Shandong Lukang PharmaceuticalLtd (SHSE:600789) A Risky Investment?

Shandong Lukang Pharmaceutical Co.,Ltd. (SHSE:600789) Surges 26% Yet Its Low P/E Is No Reason For Excitement

May 06
Shandong Lukang Pharmaceutical Co.,Ltd. (SHSE:600789) Surges 26% Yet Its Low P/E Is No Reason For Excitement

Shandong Lukang PharmaceuticalLtd's (SHSE:600789) Solid Profits Have Weak Fundamentals

Apr 03
Shandong Lukang PharmaceuticalLtd's (SHSE:600789) Solid Profits Have Weak Fundamentals

수익 및 비용 분석

Shandong Lukang PharmaceuticalLtd 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

SHSE:600789 수익, 비용 및 수입 (CNY Millions )
날짜수익수익G+A 비용R&D 비용
30 Sep 246,082401807339
30 Jun 246,240415849358
31 Mar 246,276268835354
31 Dec 236,147246811346
30 Sep 236,300239750299
30 Jun 236,122201747280
31 Mar 235,960139754276
31 Dec 225,621138696264
30 Sep 225,40292727280
30 Jun 225,20787695288
31 Mar 224,95486675271
31 Dec 214,92489699266
30 Sep 214,71486713242
30 Jun 214,60870682219
31 Mar 214,546270692212
31 Dec 204,205228627193
30 Sep 204,067250617171
30 Jun 203,879268646157
31 Mar 203,75679682144
31 Dec 193,733121702141
30 Sep 193,687119758135
30 Jun 193,606120746129
31 Mar 193,389119689132
31 Dec 183,330161674126
30 Sep 183,089215584120
30 Jun 182,901205456159
31 Mar 182,843192458124
31 Dec 172,59911443497
30 Sep 172,5765143269
30 Jun 172,542485200
31 Mar 172,492385090
31 Dec 162,506294970
30 Sep 162,485294660
30 Jun 162,500204410
31 Mar 162,43394040
31 Dec 152,41083880
30 Sep 152,296-463760
30 Jun 152,303-753810
31 Mar 152,352-1044070
31 Dec 142,312-1254090
30 Sep 142,298-174500
30 Jun 142,195-154390
31 Mar 142,169-104140
31 Dec 132,211114050

양질의 수익: 600789 has a large one-off gain of CN¥247.9M impacting its last 12 months of financial results to 30th September, 2024.

이익 마진 증가: 600789's current net profit margins (6.6%) are higher than last year (3.8%).


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: 600789's earnings have grown by 17.7% per year over the past 5 years.

성장 가속화: 600789's earnings growth over the past year (67.7%) exceeds its 5-year average (17.7% per year).

수익 대 산업: 600789 earnings growth over the past year (67.7%) exceeded the Pharmaceuticals industry -1.2%.


자기자본 수익률

높은 ROE: 600789's Return on Equity (10.3%) is considered low.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기